Literature DB >> 12681453

Functional class in patients with heart failure is associated with the development of diabetes.

Alexander Tenenbaum1, Michael Motro, Enrique Z Fisman, Jonathan Leor, Dov Freimark, Valentina Boyko, Lori Mandelzweig, Yehuda Adler, Yaniv Sherer, Solomon Behar.   

Abstract

PURPOSE: Recent reports suggest that decreased functional capacity in patients with heart failure may be associated with abnormalities in glucose metabolism. We followed patients with coronary artery disease who participated in the Bezafibrate Infarction Prevention study to determine the incidence of diabetes by baseline functional status during a 7.7-year follow-up.
METHODS: The sample comprised 2616 nondiabetic patients aged 45 to 74 years with a fasting blood glucose level <7 mmol/L (126 mg/dL). They were divided into three groups by New York Heart Association (NYHA) criteria: class I (n = 1986 patients), class II (n = 518), and class III (n = 112). The detection of a fasting blood glucose level > or =7 mmol/L during follow-up was defined as the criterion for the development of diabetes.
RESULTS: The study groups had similar demographic and clinical characteristics, except that patients with symptomatic heart failure (NYHA class II or III) were more likely to have angina. During follow-up, diabetes developed in 259 patients (13%) in NYHA class I, 76 (15%) in class II, and 22 (20%) in class III (P for trend = 0.05). At the last visit, patients in NYHA class III were twice as likely (17% [n = 19]) to have fasting blood glucose levels > or =7 mmol/L as those in NYHA class I (7.8% [n = 154]) or class II (8.7% [n = 45]) (P = 0.005). In a multivariate analysis, NYHA class III was associated with a 1.7-fold (95% confidence interval [CI]: 1.1 to 2.6) increase in the rate of development of diabetes, but NYHA class II was not (hazard ratio = 1.0; 95% CI: 0.8 to 1.3).
CONCLUSION: Among patients with coronary artery disease, advanced heart failure (NYHA class III) is associated with a significantly increased risk of developing diabetes during a 6- to 9-year follow-up.

Entities:  

Mesh:

Year:  2003        PMID: 12681453     DOI: 10.1016/s0002-9343(02)01530-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  20 in total

Review 1.  Is CaMKII a link between inflammation and hypertrophy in heart?

Authors:  Madhu V Singh; Mark E Anderson
Journal:  J Mol Med (Berl)       Date:  2011-01-29       Impact factor: 4.599

Review 2.  Cardiogenic diabetes.

Authors:  Maya Guglin; Arnaldo Villafranca; Anthony Morrison
Journal:  Heart Fail Rev       Date:  2014-09       Impact factor: 4.214

Review 3.  Echocardiographic feature of diabetic cardiomyopathy: where are we now?

Authors:  Kazuaki Negishi
Journal:  Cardiovasc Diagn Ther       Date:  2018-02

Review 4.  Glycemic variability and glycemic control in the acutely ill cardiac patient.

Authors:  Jared Moore; Kathleen Dungan
Journal:  Heart Fail Clin       Date:  2012-08-09       Impact factor: 3.179

5.  Myocardial insulin resistance induced by high fat feeding in heart failure is associated with preserved contractile function.

Authors:  Bridgette A Christopher; Hsuan-Ming Huang; Jessica M Berthiaume; Tracy A McElfresh; Xiaoqin Chen; Colleen M Croniger; Raymond F Muzic; Margaret P Chandler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-17       Impact factor: 4.733

Review 6.  Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement.

Authors:  Saifullah Nasir; David Aguilar
Journal:  Am J Cardiol       Date:  2012-11-06       Impact factor: 2.778

Review 7.  Heart Failure in Type 2 Diabetes Mellitus.

Authors:  Helena C Kenny; E Dale Abel
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

Review 8.  Insulin resistance and heart failure.

Authors:  Patrick M Heck; David P Dutka
Journal:  Curr Heart Fail Rep       Date:  2009-06

Review 9.  Combined thiazolidinedione-insulin therapy: should we be concerned about safety?

Authors:  André J Scheen
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program.

Authors:  David Preiss; Sofia Zetterstrand; John J V McMurray; Jan Ostergren; Eric L Michelson; Christopher B Granger; Salim Yusuf; Karl Swedberg; Marc A Pfeffer; Hertzel C Gerstein; Naveed Sattar
Journal:  Diabetes Care       Date:  2009-02-05       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.